Labcorp Holdings Inc. $LH Shares Bought by Legal & General Group Plc

Key Points

• Legal & General increased its stake in Labcorp by 2.0% to 689,581 shares (about 0.83% of the company), valuing its position at roughly $197.95 million, and institutional investors now own about 95.94% of the stock.
• Wall Street sentiment is mostly positive with a consensus rating of Moderate Buy (nine Buy vs. three Hold) and an average target of $304.82, as firms including JPMorgan and Robert W. Baird recently raised price targets to the low-to-mid $300s.
• Labcorp beat EPS estimates ($4.07 vs. $3.95) while revenue of $3.52B slightly missed expectations; the company set FY2026 guidance of $17.55–$18.25 EPS and pays a quarterly dividend of $0.72 (annualized $2.88, ~1.1% yield).

Legal & General Group Plc boosted its holdings in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 2.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 689,581 shares of the medical research company's stock after buying an additional 13,423 shares during the quarter. Legal & General Group Plc owned 0.83% of Labcorp worth $197,951,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Brighton Jones LLC purchased a new position in shares of Labcorp during the fourth quarter worth $991,000. Integrated Wealth Concepts LLC boosted its holdings in Labcorp by 7.9% in the first quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company's stock valued at $565,000 after purchasing an additional 177 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Labcorp by 52.2% in the first quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company's stock valued at $82,353,000 after purchasing an additional 121,304 shares during the last quarter. Savant Capital LLC grew its position in Labcorp by 3.4% during the 2nd quarter. Savant Capital LLC now owns 5,034 shares of the medical research company's stock worth $1,321,000 after purchasing an additional 164 shares during the period. Finally, Wedbush Securities Inc. acquired a new stake in Labcorp during the 2nd quarter worth about $256,000. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a report on Wednesday, February 18th. Weiss Ratings raised Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, February 10th. Morgan Stanley reiterated an "overweight" rating on shares of Labcorp in a research report on Tuesday, February 17th. Robert W. Baird boosted their price target on Labcorp from $313.00 to $326.00 and gave the company an "outperform" rating in a report on Wednesday, February 18th. Finally, Wall Street Zen upgraded Labcorp from a "hold" rating to a "buy" rating in a research report on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $304.82.

Labcorp Trading Down 2.9%

Shares of Labcorp stock opened at $262.67 on Friday. The firm has a 50-day simple moving average of $272.35 and a two-hundred day simple moving average of $270.06. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. Labcorp Holdings Inc. has a fifty-two week low of $209.38 and a fifty-two week high of $293.72. The company has a market cap of $21.64 billion, a P/E ratio of 25.11, a price-to-earnings-growth ratio of 1.85 and a beta of 1.01.

Labcorp (NYSE:LH - Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating analysts' consensus estimates of $3.95 by $0.12. The firm had revenue of $3.52 billion for the quarter, compared to analysts' expectations of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The company's quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the firm earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Friday, February 27th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Friday, February 27th. Labcorp's dividend payout ratio is presently 27.53%.

Insiders Place Their Bets

In related news, EVP Brian J. Caveney sold 1,500 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total value of $429,465.00. Following the completion of the sale, the executive vice president owned 30,107 shares of the company's stock, valued at approximately $8,619,935.17. The trade was a 4.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jonathan C. Meltzer sold 87 shares of the company's stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total transaction of $25,266.54. Following the transaction, the executive vice president owned 2,782 shares of the company's stock, valued at $807,948.44. This represents a 3.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 16,113 shares of company stock valued at $4,547,450. Corporate insiders own 0.84% of the company's stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.